Alembic Pharmaceuticals has informed the exchange that the Company's joint venture, Aleor Dermaceuticals has received US Food and Drug Administration (USFDA) Final Approval for Testosterone Topical Solution USP, 30 mg per pump actuation. The company has enclosed a press release on 16th June 2021, regarding the same.
The above information is a part of company’s filings submitted to BSE.